

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

CD154 Antibody, anti-human, FITC, REAfinity™

RRID:AB_2751146

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-612, RRID:AB_2751146

Antibody Information

URL: http://antibodyregistry.org/AB_2751146

Proper Citation: Miltenyi Biotec Cat# 130-113-612, RRID:AB_2751146

Target Antigen: CD154

Host Organism: human

Clonality: monoclonal

Comments: Antigen distribution: basophils, dendritic cells, lymphocytes, macrophages, mast cells, monocytes, NK cells, T cells

Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-469. (RRID:AB_2655260).

Antibody Name: CD154 Antibody, anti-human, FITC, REAfinity™

Description: This monoclonal targets CD154

Target Organism: human

Clone ID: clone REA238

Antibody ID: AB_2751146

Vendor: Miltenyi Biotec

Catalog Number: 130-113-612

Record Creation Time: 20250819T222443+0000

Record Last Update: 20250820T020636+0000

Ratings and Alerts

No rating or validation information has been found for CD154 Antibody, anti-human, FITC, REAfinity™.

No alerts have been found for CD154 Antibody, anti-human, FITC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Saggau C, et al. (2024) Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. *Immunity*, 57(10), 2416.

Zeng S, et al. (2023) Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. *Cell host & microbe*, 31(3), 389.

Saggau C, et al. (2022) The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. *Immunity*, 55(10), 1924.

Bacher P, et al. (2020) Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity*, 53(6), 1258.